Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency

Helena Giraldo, Cristina Laguna Benetti‐Pinto, Cristina Benetti-Pinto, Valeska Ferreira, Heraldo Garmes, Heraldo Mendes Garmes, Daniela Yela, Daniela Angerame Yela, Paulo César Giraldo, Paulo Giraldo
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2016 · vol. 33(4) , pp. 283–286 · doi:10.1080/09513590.2016.1257602 · PMID:27910707 · W2558181506
Observational OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Standard hormone therapy did not adequately improve bone density in the spine or femur of women diagnosed with premature ovarian insufficiency.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To assess standard dose hormone therapy (HT) and bone mass in premature ovarian insufficiency (POI), 239 women with POI, 132 using standard estrogen dose HT and 107 women without HT, were evaluated. All underwent bone mineral density (BMD) evaluation in the lumbar spine (LS) and total femur (TF). Mean age, age at last period and body mass index (BMI) for the untreated and for the HT groups were 38.1 ± 6.1 and 36.8 ± 7.3 years; 31.4 ± 7.3 and 30.7 ± 7.2 years; 26.6 ± 7.1 and 25.8 ± 4.6 kg/m2, respectively, (p=NS). The women taking standard dose HT started treatment at the age of 33.8 ± 6.3 years and had been on hormone treatment for 3 years at the time of the bone densitometry examination. The BMD in LS was 1.06 ± 0.15 and 1.00 ± 0.17 g/cm2 (p = 0.003); the BMD in TF was 0.92 ± 0.19 and 0.91 ± 0.13 g/cm2 (p = 0.039), respectively, for the untreated and HT groups. A 45% altered BMD (osteopenia/osteoporosis) in LS was verified in women without treatment and 60.1% in those using the standard dose TH (p = 0.01). The BMD in TF was altered in 32.3% in those without HT and 36.4% in the HT users (p = 0.34). In conclusion, standard dose HT was not adequate to reduce impaired bone mass in the spine and femur of women with POI.

My notes (saved in your browser only)

MeSH descriptors

Bone Density Estrogens Femur Hormone Replacement Therapy Lumbar Vertebrae Primary Ovarian Insufficiency Absorptiometry, Photon Adult Body Mass Index Bone Density Estrogens Estrogens Female Femur Femur Hormone Replacement Therapy Humans Lumbar Vertebrae Lumbar Vertebrae Primary Ovarian Insufficiency

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (1)

References (27)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:18:58.561258+00:00
License: CC0 · commercial use OK